1. Effect of the COVID-19 pandemic on body weight in people at high risk of type 2 diabetes referred to the English NHS Diabetes Prevention Programme.
- Author
-
Valabhji J, Barron E, Bradley D, Bakhai C, Khunti K, and Jebb S
- Subjects
- Adult, Aged, COVID-19 prevention & control, Cohort Studies, Communicable Disease Control methods, Diabetes Mellitus, Type 2 prevention & control, England epidemiology, Female, Humans, Male, Middle Aged, Self Report, Body Weight physiology, COVID-19 epidemiology, Communicable Disease Control trends, Diabetes Mellitus, Type 2 epidemiology, Program Evaluation methods, State Medicine trends
- Abstract
Competing Interests: JV is the National Clinical Director for Diabetes and Obesity at NHS England and NHS Improvement. EB is an analyst at NHS England and NHS Improvement and leads analysis of the NHS DPP. DB is an analyst at NHS England and NHS Improvement and is involved in analysis of the NHS DPP. CB is the Primary Care Advisor to the NHS DPP. KK has been a consultant and speaker for Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, and Merck Sharp & Dohme, has received grants in support of investigator and investigator-initiated trials from Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp & Dohme, Pfizer, and Boehringer Ingelheim, and has served on advisory boards for Novo Nordisk, Sanofi-Aventis, Lilly, and Merck Sharp & Dohme. KK is supported by the National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands and the NIHR Leicester Biomedical Research Centre. SJ is funded by the NIHR Oxford Biomedical Research Centre and Oxford NIHR Collaboration and Leadership in Applied Health Research. We thank Eszter Vamos (Imperial College London, London, UK) for providing statistical advice.
- Published
- 2021
- Full Text
- View/download PDF